.After a few years in biotech, Mike Quigley, Ph.D., is coming back to the pharma layer, taking up the top scientific research location at Sanofi.Quigley will definitely start Sept. 30 as the French Big Pharma's primary scientific police officer and also global director of investigation, Sanofi said to Ferocious Biotech in an emailed statement.Quigley is actually switching out Frank Nestle, M.D., who left Sanofi this spring in the middle of a global overhaul of the firm's R&D device. Nestle, that invested 8 years with the pharma, jumped over to Deerfield Administration, where he currently acts as a partner on the therapeutics team and CEO of the agency's therapeutic discovery as well as development procedures.
Quigley will participate in Sanofi from a San Francisco-based biotech that remains in stealth, according to his LinkedIn profile. He's currently specified as the company's co-founder, head of state and also chief executive officer.Because August 2021, Quigley has actually functioned as a venture companion at SV Health Investors, a medical care fund supervisor with present financial investments in biotechs including BioAge, Cerevance, Dualitas Therapeutics as well as Nimbus Therapies, among others. Quigley previously held the leading spot at Dualitas, a biotech that continues to be in secrecy, depending on to STAT.The future Sanofi innovator additionally earlier helmed Therini Bio, an immunotherapy biotech operating to build therapies for neurodegenerative illness steered through vascular disorder.Prior to spending the last few years in biotech, Quigley possesses an even longer track record in Significant Pharma, very most lately working as Gilead's senior vice head of state of research study the field of biology till the summertime of 2021. Prior to that, he clocked in greater than 4 years across numerous management roles at Bristol Myers Squibb as well as functioned as a clinical supervisor at Johnson & Johnson's Janssen upper arm prior to that.Sanofi said Quigley's objective in his new task would certainly be actually to "optimize our possibility of success by means of ideal partnerships all over our company and past, bringing best-in-class development as well as establishing and also sourcing brand-new industry-leading skill along with a devotion to variety," according to an interior memo gotten through STAT.